UA100701C2 - Композиции dhea для лечения менопаузы - Google Patents

Композиции dhea для лечения менопаузы

Info

Publication number
UA100701C2
UA100701C2 UAA201002703A UAA201002703A UA100701C2 UA 100701 C2 UA100701 C2 UA 100701C2 UA A201002703 A UAA201002703 A UA A201002703A UA A201002703 A UAA201002703 A UA A201002703A UA 100701 C2 UA100701 C2 UA 100701C2
Authority
UA
Ukraine
Prior art keywords
menopause
breast
loss
disclosed
order
Prior art date
Application number
UAA201002703A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Фернан Лабри
Original Assignee
Эндорешерш, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эндорешерш, Инк. filed Critical Эндорешерш, Инк.
Priority claimed from PCT/CA2008/001444 external-priority patent/WO2009021323A1/en
Publication of UA100701C2 publication Critical patent/UA100701C2/ru

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
UAA201002703A 2007-08-10 2008-08-08 Композиции dhea для лечения менопаузы UA100701C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96427007P 2007-08-10 2007-08-10
PCT/CA2008/001444 WO2009021323A1 (en) 2007-08-10 2008-08-08 Dhea compositions for treating menopause

Publications (1)

Publication Number Publication Date
UA100701C2 true UA100701C2 (ru) 2013-01-25

Family

ID=43618448

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201002703A UA100701C2 (ru) 2007-08-10 2008-08-08 Композиции dhea для лечения менопаузы

Country Status (3)

Country Link
AR (1) AR104577A2 (xx)
UA (1) UA100701C2 (xx)
ZA (1) ZA201000874B (xx)

Also Published As

Publication number Publication date
ZA201000874B (en) 2010-10-27
AR104577A2 (es) 2017-08-02

Similar Documents

Publication Publication Date Title
PH12013502291A1 (en) Dhea compositions for treating menopause
Bennink et al. Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women
Panjari et al. Vaginal DHEA to treat menopause related atrophy: a review of the evidence
US8349820B2 (en) Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido
BR112012014059A8 (pt) gel transdérmico de progestina / estradiol.
Labrie Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy
MX338290B (es) Tratamiento de enfermedad de alzheimer, perdida de cognición, perdida de memoria y demencia con precursores de esteroides sexuales en conbinación con moduladores selectivos del receptor de estrógenos.
NI201000184A (es) Composiciones y métodos para tratar el cáncer del seno.
CU20120175A7 (es) Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos
EA201300019A1 (ru) Способы лечения или предотвращения эстрогензависимых заболеваний
Valera et al. From the Women’s Health Initiative to the combination of estrogen and selective estrogen receptor modulators to avoid progestin addition
Gupta et al. A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause
Wang et al. The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy
JP2013500324A5 (xx)
UA100701C2 (ru) Композиции dhea для лечения менопаузы
JP2013047269A5 (xx)
TR201816243T4 (tr) Aromataz inhibitörlerinin ve antioksidanların kombinasyonları.
CU20100027A7 (es) Composiciones farmacéuticas
Suárez et al. Dehydroepiandrosterone treatment attenuates oestrogen-induced pituitary hyperplasia
JP2014508809A (ja) アンドロゲンを用いたミエリン再生
Fedotcheva et al. Dehydroepiandrosterone and Its Metabolite 5-Androstenediol: New Therapeutic Targets and Possibilities for Clinical Application
CN103054887A (zh) 一种治疗口腔溃疡的贴片
CIG Media Group Fulvestrant (Faslodex™, ICI 182,780) Is Active in Patients with Tamoxifen-Resistant Breast Cancer: Data from North American and European Randomized Trials
SG175658A1 (en) USE OF ESTRADIOL VALERATE OR 17β-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY FOR MAINTAINING AND/OR INCREASING THE FEMALE LIBIDO
de Arriba et al. Cimicifuga racemosa (CR) safety: Pre-and clinical evidence for lack of widespread estrogenic risk